PM-399
ε²Phage® cocktail
Medical need:
Implant-associated infections
High efficacy,
high precision
Pathogen:
S.aureus (incl. MRSA/MSSA)
Patient population:
2 Million infected implants p.a.
Current standard-of-care:
Debridement, implant exchange and antibiotics
Phage cocktail
PM-399 is a phage cocktail specifically assembled to treat complex S. aureus biofilms that form on implants. The phages selected for PM-399 are proprietary ε²Phages®.
Broad host range
PM-399 has a broad host range against S. aureus as well as a high aggressiveness. Bacteria cannot form resistance within lab-scale settings.
Synergy with antibiotics
Combinations of PM-399 and standard-of-care antibiotics show synergistic activity against S. aureus in-vivo.
Discovery
Lead optimization
Pre-clinical
Phase I
Phase II
Scientific Advisory Board